Adicet Bio Narrows Prula-cel Data Timeline to Q3, Outlines Pivotal Trial Path
ACET sits 52% above its 52-week low of $6.01.
Summary
Adicet Bio reported Q2 2026 results and provided a concrete timeline for its lead asset prula-cel: a Phase 1 data update in Q3 2026 with 22 LN/SLE patients, including 13 with at least 12 months of follow-up. The company also disclosed productive FDA interactions that align on a pivotal trial design for LN, with start-up activities planned for H2 2026 pending clearance. A regulatory submission for ADI-212 in solid tumors is expected in Q3, with Phase 1 initiation in Q4. The appointment of an interim CMO adds stability to clinical execution. These updates follow the Q1 report that highlighted an extended cash runway into H2 2027, giving the company room to reach these catalysts. The prula-cel data readout in Q3 is the key near-term event that could validate the platform.
At the time of this announcement, ACET was trading at $9.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.6M. The 52-week trading range was $6.01 to $17.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.